| 产品描述: | Veldoreotide (DG3173) TFA a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide TFA inhibits growth hormone (GH) secretion in adenomas compared with Octreotide . Veldoreotide has the potential to be used as pain modulating agent |
| 体外研究: |
Veldoreotide 在 HEK293 细胞中以高亲和力和效率刺激 SST2、SST4 和 SST5受体,这些细胞与 GIRK2 通道共表达;GIRK2-SST2、GIRK2-SST4 和 GIRK2-SST5 的 EC50 分别为 37.6 ± 4.5 nM、31.3 ± 14.4 nM和10.5 ± 3.4 nM。 Veldoreotide (10 μM;24小时)抑制表达 SST4 的 BON-1 细胞。 Veldoreotide (DG3173) (100 nM或1 μM;6小时) 抑制腺瘤中的GH分泌,IC50 为 0.49 nM。 |
| 参考文献: |
1. Dasgupta P, et al. Pharmacological Characterization of Veldoreotide as a Somatostatin Receptor 4 Agonist. Life (Basel). 2021 Oct 12;11(10):1075. 2. Plöckinger U, et al. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours. Eur J Endocrinol. 2012 Feb;166(2):223-34. |
| 保存条件: |
-20°C, 干燥 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
0.808 ml |
4.041 ml |
8.082 ml |
| 5 mM |
0.162 ml |
0.808 ml |
1.616 ml |
| 10 mM |
0.081 ml |
0.404 ml |
0.808 ml |
| 50 mM |
0.016 ml |
0.081 ml |
0.162 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |